These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30196110)

  • 1. Effective suppression of donor specific antibody production by Cathepsin S inhibitors in a mouse transplantation model.
    Kubo K; Kawato Y; Nakamura K; Nakajima Y; Nakagawa TY; Hanaoka K; Oshima S; Fukahori H; Inami M; Morokata T; Higashi Y
    Eur J Pharmacol; 2018 Nov; 838():145-152. PubMed ID: 30196110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
    Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
    Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
    Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
    Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive protocol with delayed use of low-dose tacrolimus after aortic transplantation suppresses donor-specific anti-MHC class I and class II antibody production in rats.
    Matia I; Fellmer P; Splith K; Varga M; Adamec M; Kämmerer I; Feldbrügge L; Krenzien F; Hau HM; Atanasov G; Schmelzle M; Jonas S
    Ann Transplant; 2014 May; 19():225-32. PubMed ID: 24815872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracing Donor-MHC Class II Reactive B cells in Mouse Cardiac Transplantation: Delayed CTLA4-Ig Treatment Prevents Memory Alloreactive B-Cell Generation.
    Yang J; Chen J; Young JS; Wang Q; Yin D; Sciammas R; Chong AS
    Transplantation; 2016 Aug; 100(8):1683-91. PubMed ID: 27362308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PI3Kδ selective inhibitor AS2541019 suppresses donor-specific antibody production in rat cardiac and non-human primate renal allotransplant models.
    Marui T; Fukahori H; Ito M; Kaneko Y; Maeda M; Tsujimoto S; Morokata T
    Int Immunopharmacol; 2019 Oct; 75():105756. PubMed ID: 31344556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bidirectional blockade of CD4 and major histocompatibility complex class II molecules: an effective immunosuppressive treatment in the mouse heart transplantation model.
    Ito H; Hamano K; Fukumoto T; Wood KJ; Esato K
    J Heart Lung Transplant; 1998 May; 17(5):460-9. PubMed ID: 9628564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
    Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
    Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
    Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
    Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens.
    Fujii H; Ivison SM; Shimizu H; Kajiwara R; Kariminia A; Yan M; Dutz JP; Schultz KR
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):546-56. PubMed ID: 22178962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of Tfh:B Cell Interactions Prevents Antibody-Mediated Rejection in a Kidney Transplant Model in Rats: Impact of Calcineurin Inhibitor Dose.
    Steines L; Poth H; Schuster A; Amann K; Banas B; Bergler T
    Front Immunol; 2021; 12():657894. PubMed ID: 34135891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mosaic of immunosuppressive drugs.
    Masri MA
    Mol Immunol; 2003 Jul; 39(17-18):1073-7. PubMed ID: 12835079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cells as antigen-presenting cells in transplantation rejection and tolerance.
    Chong AS
    Cell Immunol; 2020 Mar; 349():104061. PubMed ID: 32059816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of IL-6/IL-6R Signaling Attenuates Acute Antibody-Mediated Rejection in a Mouse Cardiac Transplantation Model.
    Ma M; Sun Q; Li X; Deng G; Zhang Y; Yang Z; Han F; Huang Z; Fang Y; Liao T; Sun Q
    Front Immunol; 2021; 12():778359. PubMed ID: 34777394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
    Shibasaki S; Yamashita K; Goto R; Wakayama K; Tsunetoshi Y; Zaitsu M; Igarashi R; Haga S; Ozaki M; Umezawa K; Todo S
    Transplantation; 2013 Feb; 95(4):542-50. PubMed ID: 23269193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 receptor signaling disruption prevents cardiac allograft deterioration in mice.
    Iida S; Omoto K; Kanemitsu I; Setoguchi K; Ishida H; Tanabe K; Suzuki T; Tashiro Y; Kishimoto H; Abe R
    Exp Clin Transplant; 2012 Aug; 10(4):375-85. PubMed ID: 22758208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
    Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
    Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAHA, an HDAC inhibitor, attenuates antibody-mediated allograft rejection.
    Zhang X; Guo M; Kang Y; Liu F; Zheng X; Han S; Fu S; Hong S; Ding G; Wang L; Wang QX
    Transplantation; 2013 Sep; 96(6):529-37. PubMed ID: 23912176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.